<span item_type="fundamental" item_id="a77db337b67d3c33dd9b23ce255516d7" counter_id="ST/US/ALT" env="prod"></span><span item_type="announcement" item_id="647882701835409409" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 1.11 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.18, beating the estimate of USD -0.2479.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -26.08 M.</p><p></p><h4>Cash and Investments</h4><p>Altimmune, Inc. reported cash, cash equivalents, and short-term investments totaling $332 million as of March 31, 2026, which increased to approximately $535 million as of April 30, 2026, reflecting net proceeds from a $225 million public offering <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. As of March 31, 2026, cash and cash equivalents were $97,601 thousand, and short-term investments were $233,939 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Revenue</h4><p>Revenue for the three months ended March 31, 2026, was $0, compared to $5 thousand in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Operating Expenses</h4><p>Research and development (R&amp;D) expenses increased to $16.2 million for the three months ended March 31, 2026, from $15.8 million in the same period in 2025, primarily due to ongoing AUD and ALD trials and startup costs for the PERFORMA Phase 3 trial in MASH, partially offset by decreased expenses from the completion of the IMPACT Phase 2b trial in MASH <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. R&amp;D expenses included $9.5 million in direct costs related to pemvidutide development activities for the quarter ended March 31, 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. General and administrative (G&amp;A) expenses were $8.1 million for the three months ended March 31, 2026, up from $6.0 million in the same period in 2025, mainly due to increased severance costs and professional fees <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Total operating expenses for the three months ended March 31, 2026, were $24,244 thousand, compared to $21,820 thousand in the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Profitability</h4><p>Loss from operations for the three months ended March 31, 2026, was - $24,244 thousand, compared to - $21,815 thousand in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Altimmune, Inc. reported a net loss of - $22.6 million for the three months ended March 31, 2026, compared to a net loss of - $19.6 million in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. The net loss per share was - $0.18 for the three months ended March 31, 2026, compared to - $0.26 in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Comprehensive loss was - $22,859 thousand for the three months ended March 31, 2026, versus - $19,605 thousand for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Other Financial Items</h4><p>Interest income was $2.9 million for the three months ended March 31, 2026, up from $1,545 thousand in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Interest expense was - $1,068 thousand for the three months ended March 31, 2026, compared to - $1 thousand in the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Other income (expense), net, was - $152 thousand for the three months ended March 31, 2026, compared to $15 thousand in the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Balance Sheet Highlights (as of March 31, 2026)</h4><p>Total current assets were $334,676 thousand, and total assets were $335,630 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Total current liabilities amounted to $11,323 thousand, with total liabilities at $51,643 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Total stockholders’ equity was $283,987 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Financing Activities</h4><p>In January 2026, Altimmune, Inc. completed a registered direct offering, generating gross proceeds of $75.0 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. In the first quarter of 2026, the company raised $8.9 million through its At-the-Market (ATM) facility <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. An oversubscribed public offering in April 2026 yielded gross proceeds of $225.0 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p><h4>Outlook / Guidance</h4><p>Altimmune, Inc. plans to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data anticipated in 2029 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>. Topline data from the RECLAIM Phase 2 AUD trial is expected in the third quarter of 2026, and enrollment completion for the RESTORE Phase 2 ALD trial is also anticipated in the third quarter of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm"></span>.</p>

Altimmune | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0